Global Real World Evidence Solutions Market – Industry Trends and Forecast to 2030

 Analyse et taille du marché des solutions de preuves du monde réel

La demande croissante de solutions RWE permet d'obtenir des informations précises et transparentes sur la sécurité et l'efficacité des nouveaux produits. En outre, le besoin de ces solutions pour détecter diverses réactions, les effets des sous-populations de produits et la valeur des produits lorsqu'ils sont utilisés par des patients complexes et comorbides augmente. Ceci, ainsi que l'essor du secteur de la santé, propulse la croissance du marché. En outre, l'utilisation croissante d'analyses avancées et de solutions technologiques dans RWE pour le développement clinique, la commercialisation, l'accélération de l'innovation et l'amélioration des résultats des soins de santé influence positivement le marché.

Data Bridge Market Research analyse que le marché des solutions de preuves du monde réel, qui s'élève à 1,48 milliard USD en 2022, devrait atteindre 4,33 milliards USD d'ici 2030, à un TCAC de 14,4 % au cours de la période de prévision 2023 à 2030. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché des solutions de preuves du monde réel  

Définition du marché

Les données du monde réel (RWE) sont des informations organisées dérivées de résultats cliniques ou de jugements basés sur des données du monde réel (RWD). Les RWD utilisent des données d'observation pour obtenir des informations, extrapoler des résultats et prévoir les maladies, les dispositifs médicaux, les populations de patients et les produits. Il s'agit d'un processus de collecte de données utilisé par le secteur de la santé pour prendre des décisions. Il rassemble des informations à partir de sources secondaires existantes, telles que des bases de données.

Dynamique du marché des solutions fondées sur des preuves du monde réel

Conducteurs

• Collaboration et innovations

Une coalition industrielle visant à innover et à étendre l’utilisation des données recueillies par les patients favorise la croissance du marché. Par exemple, en mai 2021, cinq entreprises – Aetion, IQVIA, Flatiron Health, Tempus et Syapse – ont uni leurs forces pour étendre l’utilisation des données issues des DSE, des réclamations et d’autres sources au-delà des essais cliniques. La coalition collaborera également avec des sociétés pharmaceutiques, des fabricants de dispositifs médicaux, des groupes de patients et d’autres parties prenantes clés pour soutenir des efforts plus larges autour de l’utilisation des données recueillies par les patients, qui, selon les membres, aident les développeurs, les régulateurs et les fournisseurs à mieux comprendre la sécurité et l’efficacité des produits médicaux. Ce sont ces innovations qui propulsent la croissance du marché.

• Lancements de nouveaux produits

En 2021, l'International Society for Pharmacoeconomics and Outcomes Research, une société professionnelle américaine spécialisée dans l'économie de la santé et la recherche sur les résultats, a déclaré que la Real-World Evidence Transparency Initiative avait lancé le Real-World Evidence Registry. En lançant le registre RWE et en établissant une culture de transparence pour l'analyse et la communication des RWE dans les soins de santé et la recherche en santé, la Real-World Evidence Transparency Initiative contribue à répondre aux préoccupations potentielles liées aux études RWE.

Opportunités

• Réduire les coûts de développement des médicaments et accélérer le processus de développement des médicaments

The Tufts Center for the Study of Drug Development (CSDD) reported the median cost of bringing a new drug to market, which was significantly lower than previous research. According to the study's findings, a further USD 312 million is spent on post-approval development for a lifecycle, which includes tests of new indications, formulations, and dosage strengths. As the amount of RWD increases and its accessibility increases, companies will have the opportunity to use RWE earlier in the product lifecycle to help expedite development and reduce costs.

Restraints/Challenges

• Issues such as a reluctance

Issues such as a reluctance rely on real-world studies are expected to hamper the growth of the real world evidence solutions market. In the forecast period of 2023 to 2030, the real world evidence solutions market is expected to face challenges due to a lack of universally accepted methodological standards and data processing infrastructure.

This real world evidence solutions market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the real world evidence solutions market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Real World Evidence Solutions Market

Market participants also shifted their focus to providing solutions to stem the spread of the COVID-19 pandemic, which hampered market growth. The market is expected to recover post-COVID, with a 6.07% year-on-year growth rate from 2020 to 2021. Many companies began to deploy many remote services during the pandemic, which is expected to help these companies expand their portfolios.

Recent Developments

• In 2021, Syneos Health partnered with Aetion to provide a real-world evidence solution that includes analytical-driven data and regulatory-grade data.
• In 2022, Cegedim acquired Clinityx, a French medical data expert, strengthening its position in Real-World-Data.
• In 2022, Verantos, the global leader in high-validity real-world evidence (RWE), announced the launch of the Verantos Evidence Platform.

Global Real World Evidence Solutions Market Scope

The real world evidence solutions market is segmented on the basis of component, therapeutic area and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Component

• Data Sets
• Clinical Settings Data
• Claims Data
• Pharmacy Data
• Patient-powered Data
• Services

 Therapeutic Area

• Oncology
• Cardiovascular Disease
• Neurology
• Immunology
• Others Therapeutic Areas

 End User

• Pharmaceutical and Medical Device Companies
• Healthcare Payers
• Healthcare Providers
• Other End Users

Real World Evidence Solutions Market Regional Analysis/Insights

The real world evidence solutions market is analyzed and market size insights and trends are provided by country, component, therapeutic area and end user as referenced above.

The countries covered in the real world evidence solutions market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the real world evidence solutions market due to a favourable regulatory environment, a well-established pharmaceutical industry, high number of RWE service providers, demand in clinical research activities and increasing research and development expenditure in the region.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to the growing incidence of cancer such as bladder, esophagus, liver, pancreas, and others, high presence of major manufacturers across the U.S. Furthermore, technological advancements and rising foreign investment.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The real world evidence solutions market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for real world evidence solutions market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the real world evidence solutions market. The data is available for historic period 2011-2021.

Competitive Landscape and Real World Evidence Solutions Market Share Analysis

The real world evidence solutions market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to real world evidence solutions market.

Some of the major players operating in the real world evidence solutions market are:

• IBM Corporation (U.S.)
• IQVIA (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Parexel International Corporation (U.S.)
• Optum, Inc. (U.S.)
• PerkinElmer Inc. (U.S.)
• ICON plc (Ireland)
• Oracle (U.S.)
• Cognizant (U.S.)
• Syneos Health (U.S.)
• Anthem Insurance Companies, Inc. (U.S.)
• Clinigen Limited (U.K.)
• SAS Institute Inc. (U.S.)
• Deloitte Touche Tohmatsu Limited (U.K.)
• Quantzig (India)
• Cardinal Health (U.S.)
• AmerisourceBergen Corporation (U.S.)

SKU-60273